These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35909273)

  • 1. Cancer Immunotherapy: Diverse Approaches and Obstacles.
    Sanatkar SA; Heidari A; Rezaei N
    Curr Pharm Des; 2022; 28(29):2387-2403. PubMed ID: 35909273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling new therapeutic opportunities: cytokines in prostate cancer.
    Chandran E; Meininger L; Karzai F; Madan RA
    Expert Opin Biol Ther; 2022 Oct; 22(10):1233-1243. PubMed ID: 35930001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: an alternative promising therapeutic approach against cancers.
    Gupta SL; Basu S; Soni V; Jaiswal RK
    Mol Biol Rep; 2022 Oct; 49(10):9903-9913. PubMed ID: 35759082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of natural products in cancer immunotherapy.
    Dong S; Guo X; Han F; He Z; Wang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.
    Sheikhi A; Jafarzadeh A; Kokhaei P; Hojjat-Farsangi M
    Iran J Immunol; 2016 Sep; 13(3):148-66. PubMed ID: 27671507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune evasion: insights from CRISPR screens and future directions.
    Djajawi TM; Wichmann J; Vervoort SJ; Kearney CJ
    FEBS J; 2024 Apr; 291(7):1386-1399. PubMed ID: 37971319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 15. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.
    Ghemrawi R; Abuamer L; Kremesh S; Hussien G; Ahmed R; Mousa W; Khoder G; Khair M
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns.
    Yamamoto T; Kimura T; Ueta E; Tatemoto Y; Osaki T
    Oncology; 2003; 64(4):407-15. PubMed ID: 12759539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
    Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI
    J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Cancer Immunotherapy with CRISPR-Based Technology.
    Li Z; Fei T
    Adv Biosyst; 2020 Nov; 4(11):e1900253. PubMed ID: 33245213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.